← All indications
Blindness
The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.
Subtype terms (4)
More specific conditions that are subtypes of Blindness in the MeSH hierarchy.
- Amaurosis Fugax
1 drug experimental
- Blindness, Cortical
- Deaf-Blind Disorders
- Hemianopsia
Drugs by status
Phase 4 trials (4)
Phase 2 trials (4)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (23)
- AdvanceCor GmbH
- Sanofi
- Allergan
- Applied Genetic Technologies Corp
- Neurim Pharmaceuticals Ltd.
- University of London
- Harvard University
- Los Angeles Biomedical Research Institute
- Oregon Health and Science University
- University of the Philippines
- Fudan University
- University of California, Los Angeles
- Clinilabs
- Sleep Disorders Center of Atlanta
- University of Massachusetts
- University of Nantes
- L. V. Prasad Eye Institute
- Technical University of Munich
- Thrasher Research Fund
- Kolokotrones Family Foundation
- Joseph Eye Hospital
- Editas Medicine, Inc.
- Shanghai BDgene Co., Ltd.
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (8)